Valneva SE (VALN) Other Non-Current Liabilities (2020 - 2026)
Valneva SE (VALN) posted Other Non-Current Liabilities of $14.4 million for Q1 2026, up 6.4% sequentially from $13.6 million in Q4 2025, and up 140.16% YoY from $6.0 million in Q1 2025.
Valneva SE (VALN) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Valneva SE has reported Other Non-Current Liabilities for 7 years, with the latest figure at $14.4 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 140.16% year-over-year to $14.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.4 million (up 140.16% YoY) and the FY2025 annual result came in at $13.6 million, up 2093.5% from the prior year.
- Other Non-Current Liabilities climbed to $14.4 million in Q1 2026 per VALN's latest filing, from $13.6 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $60.7 million in Q2 2022 and troughed at $583453.1 in Q4 2024.
- A 5-year average of $15.0 million and a median of $10.4 million in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities plunged 85.2% in 2022, then soared 2226.08% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $1.4 million in 2022, then retreated by 17.87% to $1.2 million in 2023, then plunged by 49.51% to $583453.1 in 2024, then surged by 2226.08% to $13.6 million in 2025, then rose by 6.4% to $14.4 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $14.4 million, $13.6 million, and $12.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.76 Mn |
| Mar 31, 2026 | 14.44 Mn |
| Dec 31, 2025 | 13.57 Mn |
| Sep 30, 2025 | 12.36 Mn |
| Jun 30, 2025 | 6.62 Mn |
| Mar 31, 2025 | 6.01 Mn |
| Dec 31, 2024 | 583,453.09 |
| Sep 30, 2024 | 8.01 Mn |
| Jun 30, 2024 | 7.50 Mn |
| Mar 31, 2024 | 10.38 Mn |
| Dec 31, 2023 | 1.16 Mn |
| Sep 30, 2023 | 10.35 Mn |
| Jun 30, 2023 | 13.77 Mn |
| Mar 31, 2023 | 25.80 Mn |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | 27.92 Mn |
| Jun 30, 2022 | 60.70 Mn |
| Mar 31, 2022 | 34.29 Mn |
| Dec 31, 2021 | 9.50 Mn |
| Dec 31, 2020 | 3.47 Mn |